drugset
Drugs / TTK-A24-567
last change Mar 2009 re-read 2 minutes ago

TTK-A24-567

Peptide

Developed for
breast cancer
Investigated by
Human Genome Center, Institute of Medical Science, University of Tokyo · Tokyo University

Trials 1 · a red edge is where a trial was stopped

today NCT00678509 · Ph 1/2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00678509 May 2008 → Mar 2009 breast cancer Tokyo University Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TTK-A24-567 “On each vaccination day, TTK-A24-567 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00678509 ↗
Modality Peptide “TTK-A24-567 peptide (1mg)” NCT00678509 ↗